Quality of Life in Patients with Atrial Fibrillation Undergoing Pulmonary Vein Isolation: Short-Term Follow-Up Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Ablation Procedure
2.3. Statistical Analysis
3. Results
3.1. Patient Characteristics
3.2. Quality of Life Assessment
3.3. Complications and Medical Therapy
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Guerra, F.; Brambatti, M.; Nieuwlaat, R.; Marcucci, M.; Dudink, E.; Crijns, H.J.G.M.; Matassini, M.V.; Capucci, A. Symptomatic atrial fibrillation and risk of cardiovascular events: Data from the Euro Heart Survey. Europace 2017, 19, 1922–1929. [Google Scholar] [CrossRef] [PubMed]
- Peigh, G.; Zhou, J.; Rosemas, S.C.; Roberts, A.I.; Longacre, C.; Nayak, T.; Schwab, G.; Soderlund, D.; Passman, R.S. Impact of Atrial Fibrillation Burden on Health Care Costs and Utilization. JACC Clin. Electrophysiol. 2024, 10, 718–730. [Google Scholar] [CrossRef] [PubMed]
- Kirchhof, P.; Camm, A.J.; Goette, A.; Brandes, A.; Eckardt, L.; Elvan, A.; Fetsch, T.; van Gelder, I.C.; Haase, D.; Haegeli, L.M.; et al. EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N. Engl. J. Med. 2020, 383, 1305–1316. [Google Scholar] [CrossRef]
- Mark, D.B.; Anstrom, K.J.; Sheng, S.; Piccini, J.P.; Baloch, K.N.; Monahan, K.H.; Daniels, M.R.; Bahnson, T.D.; Poole, J.E.; Rosenberg, Y.; et al. CABANA Investigators. Effect of Catheter Ablation vs Medical Therapy on Quality of Life among Patients with Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA 2019, 321, 1275–1285, Erratum in JAMA 2019, 321, 2370. [Google Scholar] [CrossRef]
- Calkins, H.; Hindricks, G.; Cappato, R.; Kim, Y.H.; Saad, E.B.; Aguinaga, L.; Akar, J.G.; Badhwar, V.; Brugada, J.; Camm, J.; et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2017, 14, e275–e444. [Google Scholar] [CrossRef]
- Mohanty, S.; Mohanty, P.; Di Biase, L.; Bai, R.; Pump, A.; Santangeli, P.; Burkhardt, D.; Gallinghouse, J.G.; Horton, R.; Sanchez, J.E.; et al. Impact of metabolic syndrome on procedural outcomes in patients with atrial fibrillation undergoing catheter ablation. J. Am. Coll. Cardiol. 2012, 59, 1295–1301. [Google Scholar] [CrossRef]
- Andrade, J.G.; Macle, L.; Verma, A.; Deyell, M.W.; Champagne, J.; Dubuc, M.; Leong-Sit, P.; Novak, P.; Roux, J.F.; Sapp, J.; et al. CIRCA-DOSE Study Investigators. Quality of Life and Health Care Utilization in the CIRCA-DOSE Study. JACC Clin. Electrophysiol. 2020, 6, 935–944. [Google Scholar] [CrossRef] [PubMed]
- Biviano, A.B.; Hunter, T.D.; Dandamudi, G.; Fishel, R.S.; Gidney, B.; Herweg, B.; Oza, S.R.; Patel, A.M.; Wang, H.; Pollak, S.J. Healthcare Utilization and Quality of Life Improvement after Ablation for Paroxysmal AF in Younger and Older Patients. Pacing Clin. Electrophysiol. 2017, 40, 391–400. [Google Scholar] [CrossRef]
- Aliot, E.; Botto, G.L.; Crijns, H.J.; Kirchhof, P. Quality of life in patients with atrial fibrillation: How to assess it and how to improve it. Europace 2014, 16, 787–796. [Google Scholar] [CrossRef]
- 36-Item Short Form Survey (SF-36) Scoring Instructions. Available online: https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/scoring.html (accessed on 1 November 2023).
- Pürerfellner, H.; Martinek, M.; Aichinger, J.; Nesser, H.J.; Kempen, K.; Janssen, J.P. Quality of life restored to normal in patients with atrial fibrillation after pulmonary vein ostial isolation. Am. Heart J. 2004, 148, 318–325. [Google Scholar] [CrossRef]
- Xu, Y.; Sharma, D.; Du, F.; Li, G.; Xu, G. Comparison of circumferential pulmonary vein isolation and antiarrhythmic drug therapy in patients with atrial fibrillation. Cardiol. Ther. 2012, 1, 3. [Google Scholar] [CrossRef] [PubMed]
- Woźniak-Skowerska, I.M.; Skowerski, M.J.; Hoffmann, A.; Nowak, S.; Faryan, M.; Kolasa, J.; Skowerski, T.; Szydło, K.; Wnuk-Wojnar, A.M.; Mizia-Stec, K. Quality of life in patients with paroxysmal atrial fibrillation after circumferential pulmonary vein ablation. Pol. Heart J. (Kardiol. Pol.) 2016, 74, 244–250. [Google Scholar] [CrossRef] [PubMed]
- Spertus, J.; Dorian, P.; Bubien, R.; Lewis, S.; Godejohn, D.; Reynolds, M.R.; Lakkireddy, D.R.; Wimmer, A.P.; Bhandari, A.; Burk, C. Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation. Circ. Arrhythmia Electrophysiol. 2011, 4, 15–25. [Google Scholar] [CrossRef]
- Wokhlu, A.; Monahan, K.H.; Hodge, D.O.; Asirvatham, S.J.; Friedman, P.A.; Munger, T.M.; Bradley, D.J.; Bluhm, C.M.; Haroldson, J.M.; Packer, D.L. Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. J. Am. Coll. Cardiol. 2010, 55, 2308–2316. [Google Scholar] [CrossRef] [PubMed]
- Hindricks, G.; Potpara, T.; Dagres, N.; Arbelo, E.; Bax, J.J.; Blomström-Lundqvist, C.; Boriani, G.; Castella, M.; Dan, G.A.; Dilaveris, P.E.; et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 2021, 42, 373–498. [Google Scholar] [CrossRef]
- Wazni, O.M.; Dandamudi, G.; Sood, N.; Hoyt, R.; Tyler, J.; Durrani, S.; Niebauer, M.; Makati, K.; Halperin, B.; Gauri, A.; et al. STOP AF First Trial Investigators. Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation. N. Engl. J. Med. 2021, 384, 316–324. [Google Scholar] [CrossRef]
- Andrade, J.G.; Wells, G.A.; Deyell, M.W.; Bennett, M.; Essebag, V.; Champagne, J.; Roux, J.F.; Yung, D.; Skanes, A.; Khaykin, Y.; et al. EARLY-AF Investigators. Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N. Engl. J. Med. 2021, 384, 305–315. [Google Scholar] [CrossRef]
- Yang, C.; Zhu, S.; Hui, Z.; Mo, Y. Psychosocial factors associated with medication burden among community-dwelling older people with multimorbidity. BMC Geriatr. 2023, 23, 741. [Google Scholar] [CrossRef]
- Pavlicek, V.; Wedegärtner, S.M.; Millenaar, D.; Wintrich, J.; Böhm, M.; Kindermann, I.; Ukena, C. Heart-Focused Anxiety, General Anxiety, Depression and Health-Related Quality of Life in Patients with Atrial Fibrillation Undergoing Pulmonary Vein Isolation. J. Clin. Med. 2022, 11, 1751. [Google Scholar] [CrossRef]
- Schmidt, B.; Bordignon, S.; Neven, K.; Reichlin, T.; Blaauw, Y.; Hansen, J.; Adelino, R.; Ouss, A.; Füting, A.; Roten, L.; et al. EUropean real-world outcomes with Pulsed field ablatiOn in patients with symptomatic atRIAl fibrillation: Lessons from the multi-centre EU-PORIA registry. Europace 2023, 25, euad185. [Google Scholar] [CrossRef]
- Verma, A.; Haines, D.E.; Boersma, L.V.; Sood, N.; Natale, A.; Marchlinski, F.E.; Calkins, H.; Sanders, P.; Packer, D.L.; Kuck, K.H.; et al. PULSED AF Investigators. Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial. Circulation 2023, 147, 1422–1432. [Google Scholar] [CrossRef] [PubMed]
- Demolder, A.; O’Neill, L.; El Haddad, M.; Scherr, D.; Vijgen, J.; Wolf, M.; Berte, B.; Bisbal, F.; Johannessen, A.; Rivero-Ayerza, M.; et al. No Effect of Continued Antiarrhythmic Drug Treatment on Top of Optimized Pulmonary Vein Isolation in Patients with Persistent Atrial Fibrillation: Results From the POWDER-AF2 Trial. Circ. Arrhythmia Electrophysiol. 2023, 16, e012043. [Google Scholar] [CrossRef] [PubMed]
- Kozlowski, D.; Budrejko, S.; Lip, G.Y.; Rysz, J.; Mikhailidis, D.P.; Raczak, G.; Banach, M. Lone atrial fibrillation: What do we know? Heart 2010, 96, 498–503. [Google Scholar] [CrossRef]
- Randolph, T.C.; Simon, D.N.; Thomas, L.; Allen, L.A.; Fonarow, G.C.; Gersh, B.J.; Kowey, P.R.; Reiffel, J.A.; Naccarelli, G.V.; Chan, P.S.; et al. ORBIT AF Investigators and Patients. Patient factors associated with quality of life in atrial fibrillation. Am. Heart J. 2016, 182, 135–143. [Google Scholar] [CrossRef] [PubMed]
Characteristics | n = 97 (%) |
---|---|
Gender | |
Male | 59 (60.80) |
Female | 38 (39.20) |
Age | 60.06 ± 11.61 |
Follow up duration, months | 5.98 ± 1.97 |
Atrial fibrillation | |
Paroxysmal | 65 (67.00) |
Persistent | 32 (33.00) |
Type of ablation | |
Radiofrequency | 51 (52.60) |
Cryoablation | 46 (47.40) |
Coronary artery disease | 18 (18.60) |
History of myocardial infarction | 2 (2.10) |
Chronic heart failure | 24 (24.74) |
NYHA I | 6 (6.30) |
NYHA II | 17 (17.70) |
NYHA III | 1 (1.00) |
Primary arterial hypertension | 56 (57.73) |
Grade 1 | 18 (18.60) |
Grade 2 | 36 (37.10) |
Grade 3 | 2 (2.10) |
Chronic kidney disease | 3 (3.1) |
Diabetes mellitus | 10 (10.3) |
Dyslipidemia | 25 (25.8) |
Hypothyroidism | 10 (10.4) |
Hyperthyroidism | 1 (1.0) |
Item | Index (n = 97) | Follow-Up (n = 97) | p-Value | |||
---|---|---|---|---|---|---|
Mean ± SD | Median (Q1–Q3) | Mean ± SD | Median (Q1–Q3) | |||
Physical functioning | 63.35 ± 23.94 | 65 (45–85) | 82.98 ± 21.03 | 90 (72.5–100) | <0.01 | |
Vigorous activities, such as running, lifting heavy objects, participating in strenuous sports | 25.77 ± 37.57 | 0 (0–50) | 58.76 ± 42.08 | 50 (0–100) | <0.01 | |
Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf | 65.97 ± 33.49 | 50 (50–100) | 80.92 ± 26.46 | 100 (50–100) | <0.01 | |
Lifting or carrying groceries | 62.37 ± 36.10 | 50 (50–100) | 82.98 ± 30.52 | 100 (50–100) | <0.01 | |
Climbing several flights of stairs | 43.81 ± 35.54 | 50 (0–50) | 76.80 ± 34.65 | 100 (50–100) | <0.01 | |
Climbing one flight of stairs | 79.90 ± 30.33 | 100 (50–100) | 92.78 ± 17.66 | 100 (100–100) | <0.01 | |
Bending, kneeling, or stooping | 61.34 ± 37.85 | 50 (50–100) | 83.50 ± 26.73 | 100 (50–100) | <0.01 | |
Walking more than a mile | 67.71 ± 38.37 | 100 (50–100) | 85.05 ± 27.16 | 100 (50–100) | <0.01 | |
Walking several blocks | 61.45 ± 38.02 | 50 (50–100) | 81.95 ± 31.61 | 100 (50–100) | <0.01 | |
Walking one block | 77.60 ± 31.51 | 100 (50–100) | 89.69 ± 24.93 | 100 (100–100) | <0.01 | |
Bathing or dressing yourself | 88.54 ± 22.33 | 100 (50–100) | 97.42 ± 11.11 | 100 (100–100) | <0.01 | |
Role enhancements due to physical health | 36.05 ± 40.07 | 25 (0–75) | 75.29 ± 38.31 | 100 (50–100) | <0.01 | |
Increased the amount of time you spent on work or other activities. | 46.31 ± 50.12 | 0 (0–100) | 79.76 ± 40.41 | 100 (100–100) | <0.01 | |
Accomplished more than you would like. | 36.45 ± 48.38 | 0 (0–100) | 75.25 ± 43.37 | 100 (100–100) | <0.01 | |
Expanded the range of work or other activities. | 27.83 ± 45.05 | 0 (0–100) | 76.28 ± 42.75 | 100 (100–100) | <0.01 | |
Experienced ease in performing the work or other activities. | 33.33 ± 47.38 | 0 (0–100) | 77.31 ± 42.09 | 100 (100–100) | <0.01 | |
Role enhancements due to emotional well-being | 53.26 ± 43.74 | 66.6 (0–100) | 82.13 ± 32.65 | 100 (66.6–100) | <0.01 | |
Increased the amount of time you spent on work or other activities. | 52.57 ± 50.19 | 100 (0–100) | 83.50 ± 37.30 | 100 (100–100) | <0.01 | |
Accomplished more than you would like. | 47.42 ± 50.19 | 0 (0–100) | 76.28 ± 42.75 | 100 (100–100) | <0.01 | |
Did work or other activities with extra care and attention. | 59.79 ± 49.28 | 100 (0–100) | 86.59 ± 34.24 | 100 (100–100) | <0.01 | |
Energy/fatigue | 52.88 ± 17.99 | 50 (40–70) | 70.10 ± 13.10 | 75 (62.5–75) | <0.01 | |
Did you feel full of pep? | 47.42 ± 23.15 | 40 (20–60) | 81.03 ± 22.05 | 80 (60–100) | <0.01 | |
Did you have a lot of energy? | 48.86 ± 23.97 | 40 (40–60) | 66.59 ± 17.49 | 80 (60–80) | <0.01 | |
Did you feel energized and refreshed? | 63.09 ± 22.42 | 60 (40–80) | 83.91 ± 20.13 | 100 (80–100) | <0.01 | |
Did you feel alert and full of energy? | 52.16 ± 19.26 | 40 (40–60) | 48.86 ± 26.29 | 40 (20–60) | 0.34 | |
Emotional distress | 63.21 ± 18.16 | 64 (52–76) | 54.43 ± 20.64 | 56 (36–68) | <0.01 | |
Have you been a very calm and composed person? | 59.58 ± 22.16 | 60 (40–80) | 51.13 ± 19.78 | 40 (40–60) | <0.01 | |
Have you felt consistently uplifted and positive? | 74.63 ± 23.18 | 80 (60–100) | 74.84 ± 16.14 | 80 (60–80) | 0.83 | |
Have you felt agitated and restless? | 58.76 ± 24.80 | 60 (40–80) | 56.28 ± 28.03 | 60 (50–80) | 0.67 | |
Have you felt optimistic and cheerful? | 68.86 ± 23.79 | 60 (60–80) | 55.67 ± 30.71 | 60 (20–80) | <0.01 | |
Have you been an unhappy person? | 54.22 ± 19.99 | 60 (40–60) | 34.22 ± 34.63 | 20 (0–60) | <0.01 | |
Social functioning | 73.84 ± 22.32 | 75 (62.5–87.5) | 84.89 ± 12.15 | 87.5 (75–87.5) | <0.01 | |
During the past 4 weeks, to what extent has your physical health or emotional well-being enhanced your normal social activities with family, friends, neighbors, or groups? | 67.01 ± 25.39 | 75 (50–75) | 76.03 ± 15.69 | 75 (75–75) | <0.01 | |
During the past 4 weeks, how much of the time has your physical health or emotional well-being allowed for or contributed positively to your social activities (like visiting with friends, relatives, etc.)? | 80.67 ± 24.34 | 100 (50–100) | 93.75 ± 12.56 | 100 (100–100) | <0.01 | |
Pain | 76.65 ± 21.08 | 77.5 (55–100) | 84.45 ± 14.06 | 90 (77.5–90) | <0.01 | |
No bodily pain experienced during the past 4 weeks | 78.55 ± 18.76 | 80 (60–100) | 84.12 ± 14.12 | 80 (80–100) | 0.01 | |
Pain did not interfere with normal work at all during the past 4 weeks | 74.74 ± 25.38 | 75 (50–100) | 84.79 ± 19.28 | 100 (75–100) | <0.01 | |
General health | 48.91 ± 17.14 | 45 (35–60) | 60.30 ± 15.52 | 55 (55–75) | <0.01 | |
How would you assess your general health? | 31.44 ± 19.18 | 25 (25–50) | 62.62 ± 23.96 | 75 (50–75) | <0.01 | |
I seem to have a stronger immune system than other people? | 66.75 ± 25.44 | 75 (50–100) | 64.17 ± 27.69 | 50 (50–100) | 0.61 | |
I am as healthy as anybody I know | 47.42 ± 27.83 | 50 (25–75) | 55.67 ± 26.64 | 75 (50–75) | <0.01 | |
I expect my health to improve or stay the same? | 64.69 ± 27.18 | 50 (50–100) | 76.28 ± 19.88 | 75 (75–100) | <0.01 | |
My health is excellent | 34.27 ± 30.47 | 25 (0–50) | 42.78 ± 35.34 | 50 (0–75) | 0.06 | |
Health change | 44.32 ± 21.50 | 50 (25–50) | 76.28 ± 18.53 | 75 (75–100) | <0.01 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Published by MDPI on behalf of the Lithuanian University of Health Sciences. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Linde, M.; Jubele, K.; Kupics, K.; Nikitina, A.; Erglis, A. Quality of Life in Patients with Atrial Fibrillation Undergoing Pulmonary Vein Isolation: Short-Term Follow-Up Study. Medicina 2024, 60, 1594. https://doi.org/10.3390/medicina60101594
Linde M, Jubele K, Kupics K, Nikitina A, Erglis A. Quality of Life in Patients with Atrial Fibrillation Undergoing Pulmonary Vein Isolation: Short-Term Follow-Up Study. Medicina. 2024; 60(10):1594. https://doi.org/10.3390/medicina60101594
Chicago/Turabian StyleLinde, Matiss, Kristine Jubele, Kaspars Kupics, Anastasija Nikitina, and Andrejs Erglis. 2024. "Quality of Life in Patients with Atrial Fibrillation Undergoing Pulmonary Vein Isolation: Short-Term Follow-Up Study" Medicina 60, no. 10: 1594. https://doi.org/10.3390/medicina60101594